PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Phillip K Weck, Vice President of Centocor to Speak At 9th Cytokines Conference January 27 in San Diego, California - Phillip K. Weck, will give a featured presentation on “Anti-TNF Therapies: A Case Study of Golimumab Global Development & Life Cycle Management” at the at 9th Cytokines & Inflammation Conference
Phillip K Weck, Vice President of Centocor to Speak At 9th Cytokines Conference January 27 in San Diego, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2010/12/08 - Phillip K. Weck, will give a featured presentation on “Anti-TNF Therapies: A Case Study of Golimumab Global Development & Life Cycle Management” at the at 9th Cytokines & Inflammation Conference.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Phillip K. Weck, Vice President & Compound Development Team Leader at Centocor will give a featured presentation on “Anti-TNF Therapies: A Case Study of Golimumab Global Development & Life Cycle Management” at the at 9th Cytokines & Inflammation Conference to be held in San Diego, CA on January 27-28, 2011 by GTCbio.

Golimumab was the first anti-TNF approved for three indications simultaneously in 2009 and will be the first to offer both SC and IV routes of administration. Golimumab significantly improves signs and symptoms, physical function, and health-related quality of life in subjects affected by rheumatologic disorders. Treatment with golimumab also reduces the rate of progression of structural damage associated with RA and PsA. Regulatory dossiers for these indications are submitted in over 50 countries globally with approvals in approximately 38 countries.

Golimumab is currently offered in the SmartJect® auto injector and UltraSafe® pre-filled syringes. SmartJect® and monthly dosing distinguish golimumab from other anti-TNFs and provide patient friendly administration of the product.

The 9th Cytokine and Inflammation Conference will cover ever-important topics such as the TNF family, the inflammasome, chemokines, costimulation and innate immunity. In addition, timely coverage will be devoted to areas of current rapid expansion, such as the IL-17 and Th17 fields and JAK/STAT kinases, at a time when phase 2 and even phase 3 studies are being conducted and reported in these areas. Intriguing recently discovered cytokines, such as IL-25, novel alarmins and novel IL-1 family members will also be covered.

As usual, poster sessions and opportunities for networking will complement the great roster of distinguished speakers. The organizations participating are a great selection of innovative medical organizations from academia (NIH, UCLA, UCSD, Cleveland Clinic, La Jolla Institute, Virginia Commonwealth U, U Mass, City of Hope, Scripps, Barts and the London), industry (Amgen, Pfizer, MedImmune, Novartis, Centocor/Johnson and Johnson, Biogen Idec, Incyte, Genentech, Genzyme, Chemocentryx) and, last but not -by any means- least, the US FDA.

With a 50-50 mix of academic and industry authoritative experts, the conference will cover many current and relevant aspects of cytokine biology from their respective angles. If your work focuses on basic, translational or full development cytokine biology and its applicability to human health, I encourage you to attend this conference which promises to be a fertile ground for scientific exchange and collaboration.

For more information, visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Phillip K Weck, Vice President of Centocor to Speak At 9th Cytokines Conference January 27 in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)